UpDown | The leading social platform for virtual investing. Beat the market. Earn real money. Zero risk.

You need to upgrade your Flash Player

You are now using a guest account at UpDown that will expire in 7 days on November 30. Sign up below to join the site and save your portfolio.
Note: If you already have an UpDown account , please log in.

PHARMASSET INC (VRUS) 19.66 $0.06 (0.31%) 04:40AM (15 mins delay)

VRUS

$19.66 $0.06 (0.31%)

You need to upgrade your Flash Player

Today

5d

1m

3m

1y

5y

10y

Last:	$19.66	High:	-
Prev Close:	$19.60	Low:	-
Open:	-	Mkt Cap:	$552M
Change:	$0.06 ( 0.31% )	52Wk High:	$24.60
Vol:	0	52Wk Low:	$7.62
Avg Volume:	141,853	Shares:	N/A
EPS:	-	PE Ratio:	-

Start trading VRUS with real money!

Company Description

A clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections.

	Jim Van meerten	Oct 31 1:09 PM
	VRUS - selling -- below 50 DMA http://financialtides.blo.. - VRUS Comment Comment Also post on Twitter. (What is Twitter?)

PHARMASSET INC (VRUS) Stock News & Analysis

	Pharmasset to Present at Lazard Capital Markets Healthcare Conference	11/09/2009
	Pharmasset to Webcast an Investor Event from the AASLD Meeting	11/01/2009
	An up/down market	10/31/2009	Jim Van meerten
	Pharmasset Nominates PSI-879 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development	10/06/2009
	Pharmasset to Present at JMP Securities Healthcare Conference	10/01/2009
	Pharmasset Reports Fiscal Third Quarter 2009 Financial Results	08/10/2009
	Pharmasset to Present at Canaccord Adams Conference	08/05/2009
	Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C	07/31/2009
	Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development	07/07/2009
	Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients	06/09/2009
	Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences	06/02/2009
	Pharmasset to Present at Deutsche Bank Healthcare Conference	05/14/2009
	Pharmasset Reports Fiscal Second Quarter 2009 Financial Results	05/11/2009
	Sequenom's Bombshell	04/30/2009
	Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C	04/24/2009

Write Your Own Stock Analysis

Do you have a hot tip on a stock? Share it with our community. Get started by entering the company name or symbol below.

New VRUS Stock Picks

	An up/down market
Posted 21 days ago on 10/31/09

	Optimism on Hepatitis C drug will double VRUS
Posted 554 days ago on 5/16/08

© 2009 UpDown. All Rights Reserved.

Make a suggestion for this page

Data powered by QuoteMedia (Terms of Use). Data delayed 15 minutes unless otherwise indicated.